|Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade|
SC Wei, JH Levine, AP Cogdill, Y Zhao, NAAS Anang, MC Andrews, ...
Cell 170 (6), 1120-1133. e17, 2017
|The chromatin accessibility landscape of primary human cancers|
MR Corces, JM Granja, S Shams, BH Louie, JA Seoane, W Zhou, ...
Science 362 (6413), 2018
|CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers|
S Vijayaraghavan, C Karakas, I Doostan, X Chen, T Bui, M Yi, ...
Nature communications 8 (1), 1-17, 2017
|Diacetylspermine is a novel prediagnostic serum biomarker for non–small-cell lung cancer and has additive performance with pro-surfactant protein B|
WR Wikoff, S Hanash, B DeFelice, S Miyamoto, M Barnett, Y Zhao, ...
Journal of clinical oncology 33 (33), 3880, 2015
|Sequential validation of blood-based protein biomarker candidates for early-stage pancreatic cancer|
M Capello, LE Bantis, G Scelo, Y Zhao, P Li, DS Dhillon, NJ Patel, ...
JNCI: Journal of the National Cancer Institute 109 (4), 2017
|Synthetic lethality of PARP inhibitors in combination with MYC blockade is independent of BRCA status in triple-negative breast cancer|
JPW Carey, C Karakas, T Bui, X Chen, S Vijayaraghavan, Y Zhao, J Wang, ...
Cancer research 78 (3), 742-757, 2018
|c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun|
X Xie, TS Kaoud, R Edupuganti, T Zhang, T Kogawa, Y Zhao, ...
Oncogene 36 (18), 2599-2608, 2017
|Elevation of TP53 autoantibody before CA125 in preclinical invasive epithelial ovarian cancer|
WL Yang, A Gentry-Maharaj, A Simmons, A Ryan, EO Fourkala, Z Lu, ...
Clinical Cancer Research 23 (19), 5912-5922, 2017
|Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy|
YA Lyons, S Pradeep, SY Wu, M Haemmerle, JM Hansen, MJ Wagner, ...
Oncotarget 8 (57), 96496, 2017
|MAPRE1 as a plasma biomarker for early-stage colorectal cancer and adenomas|
A Taguchi, J Rho, Q Yan, Y Zhang, Y Zhao, H Xu, SC Tripathi, H Wang, ...
Cancer Prevention Research 8 (11), 1112-1119, 2015
|Negative co-stimulation constrains T cell differentiation by imposing boundaries on possible cell states|
SC Wei, R Sharma, NAAS Anang, JH Levine, Y Zhao, JJ Mancuso, ...
Immunity 50 (4), 1084-1098. e10, 2019
|Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in CRLF2 rearranged and/or JAK driven Philadelphia chromosome–like acute B-cell …|
Q Zhang, C Shi, L Han, N Jain, KG Roberts, H Ma, T Cai, A Cavazos, ...
Oncotarget 9 (8), 8027, 2018
|The novel lncRNA lnc-NR2F1 is pro-neurogenic and mutated in human neurodevelopmental disorders|
CE Ang, Q Ma, OL Wapinski, SH Fan, RA Flynn, QY Lee, B Coe, ...
Elife 8, e41770, 2019
|Serum microRNA‐150 predicts prognosis for early‐stage non‐small cell lung cancer and promotes tumor cell proliferation by targeting tumor suppressor gene SRCIN1|
L Zhang, J Lin, Y Ye, T Oba, E Gentile, J Lian, J Wang, Y Zhao, J Gu, ...
Clinical Pharmacology & Therapeutics 103 (6), 1061-1073, 2018
|Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models|
L Han, Q Zhang, M Dail, C Shi, A Cavazos, VR Ruvolo, Y Zhao, E Kim, ...
haematologica 105 (3), 697-707, 2020
|Oral MEK 1/2 inhibitor trametinib in combination with AKT inhibitor GSK2141795 in patients with acute myeloid leukemia with RAS mutations: a phase II study|
BK Ragon, O Odenike, MR Baer, W Stock, G Borthakur, K Patel, L Han, ...
Clinical Lymphoma Myeloma and Leukemia 19 (7), 431-440. e13, 2019
|TUSC2 (FUS1)-erlotinib induced vulnerabilities in epidermal growth factor receptor (EGFR) wildtype non-small cell lung cancer (NSCLC) targeted by the repurposed drug auranofin|
C Xiaobo, M Majidi, M Feng, R Shao, J Wang, Y Zhao, ...
Scientific reports 6, 35741, 2016
|TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)|
X Cao, Y Zhao, J Wang, B Dai, E Gentile, J Lin, X Pu, L Ji, S Wu, I Meraz, ...
Oncotarget 8 (64), 107621, 2017
|Defining survivorship trajectories across patients with solid tumors: an evidence-based approach|
RL Dood, Y Zhao, SD Armbruster, RL Coleman, S Tworoger, AK Sood, ...
JAMA oncology 4 (11), 1519-1526, 2018
|High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia|
Z Zeng, W Liu, T Tsao, YH Qiu, Y Zhao, I Samudio, DD Sarbassov, ...
haematologica 102 (9), 1537-1548, 2017